Skip to content
Screener

Shattuck Labs, Inc. STTK Preferred Stock, Shares Authorized

Preferred Stock, Shares Authorized at other companies

Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$5M
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
Immunovant, Inc. logo
Immunovant, Inc.IMVT

Other financials

Income statement

See full
Revenue-
Operating income-$16.2M-24.0%
Net income-$15.2M-21.6%
EPS (diluted)-$0.12+50.0%

Balance sheet

See full
Cash & equivalents$63.3M+25.4%
Total debt$2.7M-10.0%
Total equity$211.1M+270%
Total assets$220.7M+243%

Cash flow

See full
Operating cash flow-$10.2M+2.4%
CapEx$78.0K
Free cash flow-$10.3M+1.6%

Valuation

See full
Market cap$681.93M+1,826%
Enterprise value$621.3M-5,241%
P/S681.9×+670×

Profitability

See full
Operating margin-5,578.7%-15,316pp
Net margin-5,256.8%-14,625pp
FCF margin-4,124%-23,818pp

Returns & leverage

See full
Return on equity-39.2%-12.5pp
Debt / equity0.0×
Current ratio27.6×+17.3×

Where this comes from

Reported directly by Shattuck Labs, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.

The source filing: Shattuck Labs, Inc.’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 6:57 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-055483

The Company is authorized to issue up to 300,000,000 shares of common stock and 10,000,000 shares of preferred stock, all with a par value of $0.0001 per share. The holders of the Company’s common stock are entitled to one vote per share on all matters submitted to a vote of stockholders. The Company’s common stock is not entitled to preemptive rights, and is not subject to conversion, redemption, or sinking fund provisions. Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of the Company’s common stock will receive ratably any dividends declared by the Company’s board of directors (“Board”) out of funds legally available. In the event of the Company’s liquidation, dissolution, or winding-up, the holders of the Company’s common stock will be entitled to share ratably in all assets remaining after payment of or provision for any liabilities. As of the periods presented, no common stock dividends had been declared by the Board. As of June 30, 2026, none of the 10,000,000 authorized shares of preferred stock were outstanding, and the Company has no present plans to issue any shares of preferred stock.

Item 1. Condensed Financial Statements (Unaudited)

FAQ

What is Shattuck Labs, Inc.'s preferred stock, shares authorized?
Shattuck Labs, Inc. (STTK) reported preferred stock, shares authorized of $10M in Q2 2026.
How has Shattuck Labs, Inc.'s preferred stock, shares authorized changed year-over-year?
Shattuck Labs, Inc.'s preferred stock, shares authorized decreased by 0.0% year-over-year, from $10M to $10M.
What is the long-term trend for Shattuck Labs, Inc.'s preferred stock, shares authorized?
Over 2 years (2023 to 2025), Shattuck Labs, Inc.'s preferred stock, shares authorized has grown at a 0.0% compound annual growth rate (CAGR), from $10M to $10M.
What does preferred stock, shares authorized mean?
Preferred Stock, Shares Authorized

Ask your AI about Shattuck Labs, Inc.'s preferred stock, shares authorized.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude